证券代码：603658 证券简称：安图生物 公告编号：2025-049 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 现金管理种类：国债逆回购； 现金管理金额：16,000 万元非公开发行股票闲置募集资金； 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额度范 围内，资金可在 12 个月内滚动使用。具体内容详见公司于 202 ...

Core Viewpoint - The article highlights the market capitalization changes of major domestic life science instrument manufacturers in China for 2025, indicating a mixed performance with significant growth for some companies and declines for others due to policy impacts and market dynamics [1][2]. Market Capitalization Summary - The top five companies by market capitalization in 2025 are Mindray Medical, Sunny Optical, BGI Genomics, Antu Bio, and Haier Biomedical [2]. - A total of 10 companies experienced growth in market capitalization compared to 2024, with Zhongke Meiling leading at a growth rate of +130.44% [2]. - Four companies saw a decline in market capitalization, with Antu Bio experiencing the most significant drop at -26.70% [2]. Policy Impact Analysis - The medical anti-corruption and centralized procurement policies have negatively affected the revenue of several companies, leading to a 35% decrease in equipment bidding volume in tertiary hospitals [3]. - Mindray Medical, despite being an industry leader, faced a revenue growth drop from 25% to 9% due to procurement delays and budget constraints from DRG payment reforms [3]. - Antu Bio's revenue decreased by 18% in 2024 due to the impact of centralized procurement on the prices of chemical luminescence reagents [4]. Growth Drivers - Companies are shifting towards technology innovation as traditional high-margin models and bundled sales strategies become less viable under centralized procurement [5]. - Domestic microscope manufacturers have seen significant market capitalization growth, with Sunny Optical (+47.04%), Yongxin Optical (+27.11%), and Motic (+69.22%) benefiting from increased demand and technological advancements [7]. - Zhongke Meiling achieved a market share increase from 3% to 8% by overcoming technical barriers in ultra-low temperature freezing equipment [8]. International Expansion and Market Strategy - Companies are increasingly focusing on international markets to seek new growth opportunities, with Mindray Medical expanding its factory in New Jersey as part of its international strategy [8]. - BGI Genomics and Motic are also pursuing CE/FDA certifications to enter European and American markets, indicating a shift from domestic competition to global opportunities [8].

Group 1 - The major shareholder Z&F INTERNATIONAL TRADING LIMITED holds 76,892,416 shares, accounting for 13.46% of the total share capital of the company [1] - Z&F has reduced its holdings by 260,000 shares through block trading, representing 0.05% of the total share capital [1] - The reduction took place between March 17, 2025, and June 16, 2025, with a total amount of 10,816,000.00 yuan at a price of 41.60 yuan per share [1] Group 2 - The initial reduction plan was disclosed on February 22, 2025, with a maximum intended reduction of 3% [1] - After the reduction, Z&F's current holding is 76,632,416 shares, which is 13.41% of the total share capital [1] - The actual reduction was consistent with the previously disclosed plan, and the minimum reduction quantity was achieved [1]

证券代码：603658 证券简称：安图生物 公告编号：2025-048 郑州安图生物工程股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"安图生物"或"公司"）于 2025 年 4 月 16 日召开第五届董事会第四次会议及第五届监事会第四次会议，审议通 过《关于变更注册资本暨修订<公司章程>的议案》，上述议案于 2025 年 5 月 8 日经公司 2024 年年度股东大会审议通过。具体内容详见公司分别于 2025 年 4 月 18 日及 2025 年 5 月 9 日在上海证券交易所网站（http://www.sse.com.cn）披露的 相关公告。 公司已于近日在河南省市场监督管理局办理完成注册资本的工商变更登记 和《公司章程》的备案手续，并取得了河南省市场监督管理局换发的新《营业执 照》，具体内容如下： 1. 统一社会信用代码：914100007167932103 2. 名称：郑州安图生物工程股份有限公司 5. 法定代表人：杨增利 6. 注册资本 ...

Core Insights - The 2024 revenue of the domestic instrument industry shows significant differentiation, with leading companies like Antu Bio achieving counter-cyclical growth while others face challenges due to market contraction and cost pressures [2][4] Group 1: Revenue and Income Disparities - The income of executives in the instrument sector has widened significantly compared to last year, primarily driven by high dividends [4] - Antu Bio's chairman, Miao Yongjun, is the only executive with an income exceeding 100 million yuan, with 99% of his income coming from dividends [4] - The dividend payout ratio for Antu Bio is 60.28% of net profit, while Tailin Bio has an even higher ratio of 91.94%, raising concerns about sustainable development [4] Group 2: Growth Drivers and Market Challenges - The biopharmaceutical supply chain and overseas markets are identified as core growth drivers, with Antu Bio's overseas revenue increasing by 36.25% year-on-year and Wanyi Technology achieving a remarkable 447% growth [4] - Traditional sectors like environmental monitoring and industrial process analysis are under severe pressure, as evidenced by the declining income of Xuedilong's chairman, which fell from 140 million yuan in 2022 to 110 million yuan in 2023 [5] Group 3: Cost Pressures and Profitability - Cost pressures are intensifying, squeezing net profit margins across the industry, with Tailin Bio facing significant profit margin erosion due to raw material price increases and price wars [6] - Despite a 15.01% year-on-year revenue growth, Lihua Technology experienced a decline in net profit due to rising costs and increased expenses [6] - Companies like Nanwei Technology have successfully implemented quality improvement and efficiency enhancement measures, restoring growth in core business areas while controlling expenses [6] Group 4: Executive Compensation Trends - The average pre-tax salary of executives has decreased to approximately 860,000 yuan, down from 1.2 million yuan last year, reflecting cost-cutting measures amid profit pressures [9] - The compensation structure for executives in the instrument industry is evolving, emphasizing the importance of strategic transformation, industry upgrades, and cost management [9]

Group 1 - The major shareholder Z&FINTERNATIONALTRADINGLIMITED has completed its share reduction plan on June 16, 2025 [1] - The company has a total inventory of 1 billion, and it follows accounting standards for inventory impairment [1] - The controlling shareholder, Antu Industrial, completed its previous share increase plan on February 20, 2025, acquiring 5,541,300 shares [1] Group 2 - The accounts receivable turnover rate has decreased from 7.25 times in 2017 to 3.9 times in 2024 due to the expansion of the overall service business, which has a longer collection cycle [1]

证券代码：603658 证券简称：安图生物 公告编号：2025-046 郑州安图生物工程股份有限公司 | 持股比例 | 13.46% | | --- | --- | | 当前持股股份来源 | IPO 前取得：59,148,012股 | | | 其他方式取得：17,744,404股 | 持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 Z&F INTERNATIONAL TRADING LIMITED（以下简称"Z&F"） 持有郑州安图生物工程股份有限公司股份（以下简称"公司"或"安 图生物"）76,892,416 股，占本公司总股本的 13.46%，股份来源为公 司首次公开发行股票并上市前已发行的股份和权益分派资本公积转增 股本取得的股份。 减持计划的实施结果情况 安图生物于 2025 年 6 月 16 日收到 Z&F 发来的《关于减持郑州安 图生物工程股份有限公司股票结果的函》。截至 2025 年 6 月 16 日，Z&F 通过大宗交易方式累计 ...

郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、非公开发行股票闲置募集资金进行现金管理情况 1 现金管理种类：券商收益凭证； 现金管理金额：10,000 万元非公开发行股票闲置募集资金； 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额度范 围内，资金可在 12 个月内滚动使用。具体内容详见公司于 2024 年 12 月 12 日在上 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-045 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 现金管理种类：大额存单、券商收益凭证、国债逆回购； 现金管理金额：14,000 万元公开发行可转换公司债券闲置募集资金；58,000 万元非公开发行股票闲置募集资金。 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-044 郑州安图生物工程股份有限公司 关于开立募集资金现金管理产品专用结算账户的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上述产品专户将仅用于公司2020年非公开发行股票闲置募集资金现金管理结算， 不会用于存放非募集资金或用作其他用途，公司将在现金管理产品到期且无下一 步使用或购买计划时及时注销该账户。 二、风险控制措施 1、公司将严格按照《上海证券交易所股票上市规则》《上市公司监管指引 第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》《公司章程》等法律法规办理相关现 金管理业务； 2、公司将根据市场情况及时跟踪投资产品投向，如果发现潜在的风险因素， 将进行评估，并针对评估结果采取报告制度，及时采取相应的保全措施，控制投 资风险； 郑州安图生物工程股份有限公司（以下简称"公司"）于2024年12月11日召 开第五届董事会第二次会议、第五届监事会第二次会议，审议通过《关于使用闲 置募集资 ...